SERMs: SERMs are the most preferred type of treatment for ERα-positive breast cancer and they act by binding to ERα and suppress E2-regulated gene expression by enhancing corepressor instead of coactivator recruitment to ERα [56]. Here, ESR1 is linked to breast carcinoma.